Loading
Latest filing published 11 Mar 2022 for Eiger BioPharmaceuticals, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Only one filing by David A. Cory is known so far (11 March 2022): a share grant, in Eiger BioPharmaceuticals, Inc. That is too little to draw conclusions. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration